Label: CLINDAMYCIN capsule

  • NDC Code(s): 69043-013-20, 69043-014-20, 69043-015-01, 69043-015-05, view more
    69043-016-01
  • Packager: Cronus Pharma LLC
  • Category: PRESCRIPTION ANIMAL DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Animal Drug Application

Drug Label Information

Updated October 22, 2021

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    For Use In Dogs Only

    Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • DESCRIPTION

    Clindamycin Hydrochloride Capsules, USP contain clindamycin hydrochloride which is the hydrated salt of clindamycin. Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chlorosubstitution of the 7(R)-hydroxyl group of a naturally produced antibiotic produced by Streptomyces lincolnensis var. lincolnensis.

    Clindamycin Hydrochloride Capsules, USP (For Use in Dogs Only):

    25 mg Capsule, each yellow and colorless capsule contains clindamycin hydrochloride equivalent to 25 mg of clindamycin.

    75 mg Capsule, each green and colorless capsule contains clindamycin hydrochloride equivalent to 75 mg of clindamycin.

    150 mg Capsule, each blue and colorless capsule contains clindamycin hydrochloride equivalent to  150 mg of clindamycin.

    300 mg Capsule, each turquoise and colorless capsule contains clindamycin hydrochloride equivalent to 300 mg of clindamycin.

  • CLINICAL PHARMACOLOGY

    Absorption
    Clindamycin hydrochloride is rapidly absorbed from the canine gastrointestinal tract.

    Dog Serum Levels
    Serum levels at or above 0.5 µg/mL can be maintained by oral dosing at a rate of 2.5 mg/lb of clindamycin hydrochloride every 12 hours. This same study revealed that average peak serum concentrations of clindamycin occur 1 hour and 15 minutes after oral dosing. The elimination half -life for clindamycin in dog serum was approximately 5 hours. There was no bioactivity accumulation after a regimen of multiple oral doses in healthy dogs.

    Clindamycin Serum Concentrations 2.5 mg/lb (5.5 mg/kg) After B.I.D. Oral Dose of Clindamycin Hydrochloride Capsules to Dogs

    clindamycin

    Metabolism and Excretion

    Extensive studies of the metabolism and excretion of clindamycin hydrochloride administered orally in animals and humans have shown that unchanged drug and bioactive and bioinactive metabolites are excreted in urine and feces. Almost all of the bioactivity detected in serum after clindamycin hydrochloride product administration is due to the parent molecule (clindamycin). Urine bioactivity, however, reflects a mixture of clindamycin and active metabolites, especially N-demethyl clindamycin and clindamycin sulfoxide.

    Site and Mode of Action
    Clindamycin is an inhibitor of protein synthesis in the bacterial cell. The site of binding appears to be in the 50S sub-unit of the ribosome. Binding occurs to the soluble RNA fraction of certain ribosomes, thereby inhibiting the binding of amino acids to those ribosomes. Clindamycin differs from cell wall inhibitors in that it causes irreversible modification of the protein-synthesizing subcellular elements at the ribosomal level.

    Microbiology
    Clindamycin is a lincosaminide antimicrobial agent with activity against a wide variety of aerobic and anaerobic bacterial pathogens. Clindamycin is a bacteriostatic compound that inhibits bacterial protein synthesis by binding to the 50S ribosomal sub-unit. The minimum inhibitory concentrations (MICs) of Gram-positive and obligate anaerobic pathogens isolated from dogs in the United States are presented in Table 1. Bacteria were isolated in 1998-1999. All MICs were performed in accordance with the Clinical and Laboratory Standards Institute (CLSI).

    Table 1. Clindamycin MIC Values (µg/mL) from Diagnostic Laboratory Survey Data Evaluating Canine Pathogens in the U.S. during 1998-991
    OrganismNumber of IsolatesMIC50MIC85MIC90Range
    Soft Tissue/Wound2
    Staphylococcus aureus170.50.5≥ 4.00.25- ≥ 4.0
    Staphylococcus intermedius280.250.5≥ 4.00.125- ≥ 4.0
    Staphylococcus spp180.50.5≥ 4.00.25- ≥ 4.0
    Beta-hemolytic streptococci460.50.5≥ 4.00.25- ≥ 4.0
    Streptococcus spp110.5≥ 4.0≥ 4.00.25-≥ 4.0
    Osteomyelitis/Bone3
    Staphylococcus aureus200.50.50.50.54
    Staphylococcus intermedius150.5≥ 4.0≥ 4.00.25-≥ 4.0
    Staphylococcus spp180.5≥ 4.0≥ 4.00.25-≥ 4.0
    Beta-hemolytic streptococci210.52.02.00.25-≥ 4.0
    Streptococcus spp21≥ 4.0≥ 4.0≥ 4.00.25-≥ 4.0
    Dermal/Skin5
    Staphylococcus aureus250.5≥ 4.0≥ 4.00.25-≥ 4.0
    Staphylococcus intermedius480.5≥ 4.0≥ 4.00.125- ≥ 4.0
    Staphylococcus spp320.5≥ 4.0≥ 4.00.25-≥ 4.0
    Beta-hemolytic streptococci170.50.50.50.25-0.5

    1 The correlation between the in vitro susceptibility data and clinical response has not been determined.

    2 Soft Tissue/Wound: includes samples labeled wound, abscess, aspirate, exudates, draining tract, lesion, and mass.

    3 Osteomyelitis/Bone: includes samples labeled bone, fracture, joint, tendon
    4 No range, all isolates yielded the same value
    5 Dermal/Skin: includes labeled skin, skin swab, biopsy, incision, lip

  • INDICATIONS

    Clindamycin Hydrochloride Capsules, USP (for use in dogs only) are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below:

    Dogs: Skin infections (wounds and abscesses) due to coagulase positive staphylococci (Staphylococcus aureus or Staphylococcus intermedius). Deep wounds and abscesses due to Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.

    Dental infections due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens. Osteomyelitis due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.

  • CONTRAINDICATIONS

    Clindamycin Hydrochloride Capsules, USP are contraindicated in animals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

    Because of potential adverse gastrointestinal effects, do not administer to rabbits, hamsters, guinea pigs, horses, chinchillas or ruminating animals.

  • WARNINGS

    Keep out of reach of children. Not for human use.

  • PRECAUTIONS

    During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed.

    The use of Clindamycin Hydrochloride Capsules, USP occasionally results in overgrowth of non-susceptible organisms such as clostridia and yeasts. Therefore, the administration of Clindamycin Hydrochloride Capsules should be avoided in those species sensitive to the gastrointestinal effects of clindamycin (see CONTRAINDICATIONS). Should superinfections occur, appropriate measures should be taken as indicated by the clinical situation.

    Patients with very severe renal disease and/or very severe hepatic disease accompanied by severe metabolic aberrations should be dosed with caution, and serum clindamycin levels monitored during high-dose therapy.

    Clindamycin hydrochloride has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, Clindamycin Hydrochloride Capsules, USP should be used with caution in animals receiving such agents.

    Safety in gestating bitches and queens or breeding male dogs has not been established.

  • ADVERSE REACTIONS

    Side effects occasionally observed in either clinical trials or during clinical use were vomiting and diarrhea.

    To report a suspected adverse reaction call 1-844-227-6687 (1-844-2-CRONUS)


  • DOSAGE AND ADMINISTRATION

    Dogs: Infected Wounds, Abscesses, and Dental Infections
    Oral: 2.5-15.0 mg/lb body weight every 12 hours.

    Duration: Treatment with Clindamycin Hydrochloride capsules, USP may be continued up to a maximum of 28 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three or four days if no response to therapy is seen.

    Dosage Schedule

    Capsules
    Clindamycin Hydrochloride Capsules, USP 25 mg, administer 1-6 capsules every 12 hours for each 10 pounds of body weight.
    Clindamycin Hydrochloride Capsules, USP 75 mg, administer 1 -6 capsules every 12 hours for each 30 pounds of body weight.
    Clindamycin Hydrochloride Capsules, USP 150 mg, administer 1-6 capsules every 12 hours for each 60 pounds of body weight.
    Clindamycin Hydrochloride Capsules, USP 300 mg, administer 1-6 capsules every 12 hours for each 120 pounds of body weight.

    Dogs: Osteomyelitis
    Oral: 5.0-15.0 mg/lb body weight every 12 hours.

    Duration: Treatment with Clindamycin Hydrochloride Capsules is recommended for a minimum of 28 days. Treatment should not be continued for longer than 28 days if no response to therapy is seen.

    Dosage Schedule:

    Capsules
    Clindamycin Hydrochloride Capsules, USP 25 mg, administer 2-6 capsules every 12 hours for each 10 pounds of body weight.
    Clindamycin Hydrochloride Capsules, USP 75 mg, administer 2 -6 capsules every 12 hours for each 30 pounds of body weight.
    Clindamycin Hydrochloride Capsules, USP 150 mg, administer 2-6 capsules every 12 hours for each 60 pounds of body weight.
    Clindamycin Hydrochloride Capsules, USP 300 mg, administer 2-6 capsules every 12 hours for each 120 pounds of body weight

  • ANIMAL SAFETY SUMMARY 

    Rat and Dog Data: One year oral toxicity studies in rats and dogs at doses of 30, 100 and 300 mg/kg/day (13.6, 45.5 and 136.4 mg/lb/day) have shown clindamycin hydrochloride capsules to be well tolerated. Differences did not occur in the parameters evaluated to assess toxicity when comparing groups of treated animals with contemporary controls. Rats administered clindamycin hydrochloride at 600 mg/kg/day (272.7 mg/lb/day) for six months tolerated the drug well; however, dogs orally dosed at 600 mg/kg/day (272.7 mg/lb/day) vomited, had anorexia, and subsequently lost weight. At necropsy these dogs had erosive gastritis and focal areas of necrosis of the mucosa of the gallbladder.

    Safety in gestating bitches or breeding males has not been established.

  • STORAGE

    Store at controlled room temperature 68° to 77°F (20° to 25°C).


    How Supplied
    Clindamycin Hydrochloride Capsules are available as:
    25 mg -  bottles of 200
    75 mg - bottles of 200
    150 mg - bottles of 100 and 500
    300 mg - bottles of 100

    To report suspected adverse drug events, for technical assistance or to obtain a copy of the safety data sheet (SDS), contact Cronus Pharma LLC at 1-844-227-6687 or 1-844-2-CRONUS.

    For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at https://www.fda.gov/animal-veterinary/safety-health.

    Approved by FDA under ANADA # 200-298
    Manufactured for:
    Cronus Pharma LLC,
    East Brunswick, NJ 08816.
    Contact No: 1-844-227-6687
    (1-844-2-CRONUS)

    Made in India

    Distributed by:
    Cronus Pharma LLC
    2 Tower Center Boulevard, Suite 1101A,
    East Brunswick, NJ 08816
    Contact No: 1-844-227-6687 (1-844-2-CRONUS)
    e-Fax No: 732-647-1272
    Email: contact@cronuspharma.com
    Issued: 08/2019

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    NDC 69043-013-20

    Clindamycin Hydrochloride Capsules, USP

    25 mg

    Equivalent to 25 mg clindamycin

    Approved by FDA under ANADA # 200-298

    CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

    200 Capsules

    For Use in Dogs Only

    25mg container

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    NDC 69043-014-20

    Clindamycin Hydrochloride Capsules, USP

    75 mg

    Equivalent to 75 mg clindamycin

    Approved by FDA under ANADA # 200-298

    CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

    200 Capsules

    For Use in Dogs Only

    75mg container

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    NDC 69043-015-01

    Clindamycin Hydrochloride Capsules, USP

    150 mg

    Equivalent to 150 mg clindamycin

    Approved by FDA under ANADA # 200-298

    CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

    100 Capsules

    For Use in Dogs Only

    150mg-100s container

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    NDC 69043-015-05

    Clindamycin Hydrochloride Capsules, USP

    150 mg

    Equivalent to 150 mg clindamycin

    Approved by FDA under ANADA # 200-298

    CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

    500 Capsules

    For Use in Dogs Only

    150mg-500s container

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    NDC 69043-016-01

    Clindamycin Hydrochloride Capsules, USP

    300 mg

    Equivalent to 300 mg clindamycin

    Approved by FDA under ANADA # 200-298

    CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

    100 Capsules

    For Use in Dogs Only

    300mg container.jpg

  • INGREDIENTS AND APPEARANCE
    CLINDAMYCIN 
    clindamycin capsule
    Product Information
    Product TypePRESCRIPTION ANIMAL DRUGItem Code (Source)NDC:69043-013
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    CLINDAMYCIN HYDROCHLORIDE (UNII: T20OQ1YN1W) (CLINDAMYCIN - UNII:3U02EL437C) CLINDAMYCIN25 mg
    Product Characteristics
    ColorYELLOW (YELLOW-WHITE) Scoreno score
    ShapeCAPSULESize16mm
    FlavorImprint Code CRONUS;CLIN25
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:69043-013-20200 in 1 BOTTLE
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANADAANADA20029810/04/2019
    CLINDAMYCIN 
    clindamycin capsule
    Product Information
    Product TypePRESCRIPTION ANIMAL DRUGItem Code (Source)NDC:69043-014
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    CLINDAMYCIN HYDROCHLORIDE (UNII: T20OQ1YN1W) (CLINDAMYCIN - UNII:3U02EL437C) CLINDAMYCIN75 mg
    Product Characteristics
    ColorGREEN (GREEN-WHITE) Scoreno score
    ShapeCAPSULESize16mm
    FlavorImprint Code CRONUS;CLIN75
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:69043-014-20200 in 1 BOTTLE
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANADAANADA20029810/04/2019
    CLINDAMYCIN 
    clindamycin capsule
    Product Information
    Product TypePRESCRIPTION ANIMAL DRUGItem Code (Source)NDC:69043-015
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    CLINDAMYCIN HYDROCHLORIDE (UNII: T20OQ1YN1W) (CLINDAMYCIN - UNII:3U02EL437C) CLINDAMYCIN150 mg
    Product Characteristics
    ColorBLUE (BLUE-WHITE) Scoreno score
    ShapeCAPSULESize19mm
    FlavorImprint Code CRONUS;CLIN150
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:69043-015-01100 in 1 BOTTLE
    2NDC:69043-015-05500 in 1 BOTTLE
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANADAANADA20029810/04/2019
    CLINDAMYCIN 
    clindamycin capsule
    Product Information
    Product TypePRESCRIPTION ANIMAL DRUGItem Code (Source)NDC:69043-016
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    CLINDAMYCIN HYDROCHLORIDE (UNII: T20OQ1YN1W) (CLINDAMYCIN - UNII:3U02EL437C) CLINDAMYCIN300 mg
    Product Characteristics
    ColorTURQUOISE (TURQUOISE-WHITE) Scoreno score
    ShapeCAPSULESize22mm
    FlavorImprint Code CRONUS;CLIN300
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:69043-016-01100 in 1 BOTTLE
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANADAANADA20029810/04/2019
    Labeler - Cronus Pharma LLC (079421067)